Kodiak Sciences Inc. (KOD)
Down -28.08% in 4 Weeks, Here's Why You Should You Buy the Dip in Kodiak Sciences (KOD)
Kodiak Sciences (KOD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Kodiak Q4 Loss Narrower Than Expected, Pipeline Development in Focus
KOD reports a narrower-than-expected loss for the fourth quarter of 2024. The company provides updates regarding its pipeline development plans.
Kodiak Sciences: Anti-VEGF Could Win Nicely On Retinal Disorders
Kodiak Sciences basically uses a novel biopolymer conjugate platform to develop more durable, next-generation retinal disease therapies. Today, KOD's pipeline includes Phase 3 candidates for DR, RVO, and wet AMD, targeting an $18 billion TAM by 2028. The main catalyst to watch now is their upcoming pivotal data in 2026 that could lead to FDA approval by 2027.
KOD Stock Rallies 271% in 6 Months on Eye Disease Program Updates
Kodiak stock skyrockets 271% in six months on the back of positive updates from the tarcocimab program for treating retinal vascular diseases.
KOD Stock Up as Jefferies Upgrades Rating on Huge Pipeline Potential
Kodiak stock surges as Jefferies upgrades it to a "BUY" rating based on the significant potential of its pipeline candidates for retinal disease indications.
Eye-Disease Focused Kodiak Sciences Is A Promising 'Turnaround Story For 2025': Analyst Upgrades Stock
Jefferies has upgraded Kodiak Sciences Inc. KOD, a biopharmaceutical company focused on retinal (eye) diseases.
Kodiak Sciences Inc. (KOD) Just Flashed Golden Cross Signal: Do You Buy?
Kodiak Sciences Inc. (KOD) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, KOD's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.
Kodiak Q3 Loss Narrower Than Expected, Pipeline Development in Focus
KOD reports a narrower-than-expected loss for the third quarter of 2024. The company provides updates regarding its pipeline development plans.
Kodiak Counts on Tarcocimab Eye Disease Program Despite Setbacks
KOD is evaluating tarcocimab in a phase III diabetic retinopathy study, which is set to form the basis for a regulatory filing across three eye disease indications.
Why Is Kodiak Sciences (KOD) Down 8.1% Since Last Earnings Report?
Kodiak Sciences (KOD) reported earnings 30 days ago. What's next for the stock?
Kodiak (KOD) Q2 Loss Narrower Than Expected, Pipeline in Focus
Kodiak (KOD) reports a narrower-than-expected loss for the second quarter of 2024. The company provides updates regarding its pipeline development plans.
All You Need to Know About Kodiak Sciences (KOD) Rating Upgrade to Buy
Kodiak Sciences (KOD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
